Relay Therapeutics Files 8-K on Security Holder Vote Matters

TL;DR

RLAY filed an 8-K for a shareholder vote. Details TBD.

AI Summary

Relay Therapeutics, Inc. filed an 8-K on June 3, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any financial figures.

Why It Matters

This filing indicates that Relay Therapeutics is convening a meeting or seeking shareholder approval for certain corporate actions, which could impact governance or strategic direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new financial information or material events that would immediately impact the company's risk profile.

Key Players & Entities

• Relay Therapeutics, Inc. (company) — Registrant
• June 03, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share RLAY Nasdaq Global Market

Filing Documents

• rlay-20240603.htm (8-K) — 55KB
• 0000950170-24-067952.txt ( ) — 162KB
• rlay-20240603.xsd (EX-101.SCH) — 23KB
• rlay-20240603_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 3, 2024, Relay Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote on the three proposals set forth below, each of which is described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2024. The final voting results are set forth below. Proposal 1. Election of directors. The Company's stockholders elected each of the following individuals to serve as class I directors for a three-year term ending at the Company's 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Name Votes For Votes Withheld Broker Non-Votes Sanjiv K. Patel, M.D. 109,894,794.00 1,587,504.00 8,190,121.00 Linda A. Hill, Ph.D. 91,335,004.00 20,111,439.00 8,225,976.00 Proposal 2. Non-binding advisory vote on executive compensation. The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 66,749,846.00 44,678,968.00 53,582.00 8,190,023.00 Proposal 3. Ratification of appointment of independent registered public accounting firm. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 119,407,293.00 19,856.00 245,270.00 0.00 No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RELAY THERAPEUTICS, INC. Date: June 3, 2024 By: /s/ Brian Adams Brian Adams Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR